pure_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2013
PURE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
Delaware
|
|
001-14468
|
|
33-0530289
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
| |
|
|
1725 Gillespie Way
El Cajon, California
|
|
92020
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (619) 596-8600
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On April 24, 2013, PURE Bioscience, Inc. (the “Company”) received a determination from the NASDAQ Listing Qualifications Panel (the “Panel”) indicating that the Panel has granted the Company’s request for continued listing on The NASDAQ Capital Market pursuant to an extension through June 18, 2013 to evidence compliance with the minimum $2.5 million stockholders’ equity requirement and its ability to sustain compliance with the minimum threshold over the long term.
The determination follows the Company’s hearing before the Panel on April 4, 2013, at which the Panel considered the Company’s plan to regain and sustain compliance with the minimum stockholders’ equity requirement. While the Company is working diligently to satisfy the stockholders’ equity requirement, there can be no assurance that the Company will be able to timely do so.
On April 25, 2013, the Company issued a press release announcing that it had received the Panel determination letter described above. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
|
Title
|
| |
|
|
|
99.1
|
|
Press Release of PURE Bioscience, Inc. dated April 25, 2013.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
PURE BIOSCIENCE, INC.
|
| |
|
| |
|
|
Dated: April 25, 2013
|
By: /s/ Michael L. Krall
|
| |
Michael L. Krall
|
| |
President, Chief Executive Officer
|
| |
(Principal Executive Officer)
|
| |
|
| |
|
EXHIBIT INDEX
|
99.1
|
Press Release of PURE Bioscience, Inc. dated April 25, 2013.
|